Gulnara Abdrashidovna Yuldasheva
Gulnara Abdrashidovna Yuldasheva has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Aleksandr I. Ilin
Scientific Centre for Anti-Infectious Drugs
3 shared publicationsGeorgii M. Zhidomirov
Boreskov Institute of Catalysis SB RAS
3 shared publications- Alexander Ilin
JSC Scientific Center for Anti-Infectious Drugs, Almaty 050060, Kazakhstan
2 shared publications - Anar Seisembekova
Al Farabi Kazakh National University
2 shared publications - Ardak B. Jumagaziyeva
Scientific Center for Anti-Infectious Drugs JSC, Almaty 050060, Kazakhstan
2 shared publications - Dana Askarova
JSC Scientific Center for Anti-Infectious Drugs, Almaty 050060, Kazakhstan
2 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4292
Iodine-Based Coordination Compounds: A Strategy Toward Antibiotic Potentiation
Due to the increasing threat of antibiotic resistance and the emergence of new pathogenic strains, the development of effective combined therapeutic agents represents a crucial direction in the fight against infections. Within this study, several compounds were synthesized in which iodine is present in a coordination complex with antibiotics—sodium sulfadimidine and gentamicin sulfate. The physicochemical parameters of these compounds were investigated using capillary electrophoresis and UV spectroscopy, along with their cytotoxicity, antimicrobial, and antiviral activities. As a result of this work, two stable compounds, KC-246 and KC-248, were synthesized, demonstrating virus-inhibitory activity against herpes simplex virus and influenza A under extremely low cytotoxicity levels of 0.018–0.106 mg/mL. Additionally, they exhibited antimicrobial activity against representatives of the families Staphylococcaceae, Pseudomonadaceae, Enterobacteriaceae, Enterococcaceae, and yeast-like fungi. The minimum bactericidal concentrations (MBCs) ranged from 0.794 µg/mL to 0.198 µg/mL (KC-246) and from 2.093 µg/mL to 0.523 µg/mL (KC-248).
- 12 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4292
Open AccessIodine-Based Coordination Compounds: A Strategy Toward Antibiotic Potentiation
Due to the increasing threat of antibiotic resistance and the emergence of new pathogenic strains, the development of effective combined therapeutic agents represents a crucial direction in the fight against infections. Within this study, several compounds were synthesized in which iodine is present in a coordination complex with antibiotics—sodium sulfadimidine and gentamicin sulfate. The physicochemical parameters of these compounds were investigated using capillary electrophoresis and UV spectroscopy, along with their cytotoxicity, antimicrobial, and antiviral activities. As a result of this work, two stable compounds, KC-246 and KC-248, were synthesized, demonstrating virus-inhibitory activity against herpes simplex virus and influenza A under extremely low cytotoxicity levels of 0.018–0.106 mg/mL. Additionally, they exhibited antimicrobial activity against representatives of the families Staphylococcaceae, Pseudomonadaceae, Enterobacteriaceae, Enterococcaceae, and yeast-like fungi. The minimum bactericidal concentrations (MBCs) ranged from 0.794 µg/mL to 0.198 µg/mL (KC-246) and from 2.093 µg/mL to 0.523 µg/mL (KC-248).
- Open Access
- 15 April 2026
- Published by MDPI AG in Preprints.org
Iodine-Based Coordination Compounds: A Strategy Toward Antibiotic Potentiation
Due to the increasing threat of antibiotic resistance and the emergence of new pathogenic strains, the development of effective combined therapeutic agents represents a crucial direction in the fight against infections. Within this study, several compounds were synthesized in which iodine is present in a coordination complex with antibiotics – sodium sulfathimidine and gentamicin sulfate. The physicochemical parameters of these compounds were investigated using capillary electrophoresis and UV-spectroscopy, along with their cytotoxicity, antimicrobial, and antiviral activities. As a result of this work, two stable compounds, KC-246 and KC-248, were synthesized, demonstrating virus-inhibitory activity against herpes simplex virus and influenza A under extremely low cytotoxicity levels of 0.018–0.106 mg/ml. Additionally, they exhibited antimicrobial activity against representatives of the families Staphylococcaceae, Pseudomonadaceae, Enterobacteriaceae, Enterococcaceae, and yeast-like fungi. The minimum bactericidal concentrations (MBCs) ranged from 0.794 µg/ml to 0.198 µg/ml (KC-246) and from 2.093 µg/ml to 0.523 µg/ml (KC-248).
- 15 April 2026
- Published by MDPI AG in Preprints.org
Open AccessIodine-Based Coordination Compounds: A Strategy Toward Antibiotic Potentiation
Due to the increasing threat of antibiotic resistance and the emergence of new pathogenic strains, the development of effective combined therapeutic agents represents a crucial direction in the fight against infections. Within this study, several compounds were synthesized in which iodine is present in a coordination complex with antibiotics – sodium sulfathimidine and gentamicin sulfate. The physicochemical parameters of these compounds were investigated using capillary electrophoresis and UV-spectroscopy, along with their cytotoxicity, antimicrobial, and antiviral activities. As a result of this work, two stable compounds, KC-246 and KC-248, were synthesized, demonstrating virus-inhibitory activity against herpes simplex virus and influenza A under extremely low cytotoxicity levels of 0.018–0.106 mg/ml. Additionally, they exhibited antimicrobial activity against representatives of the families Staphylococcaceae, Pseudomonadaceae, Enterobacteriaceae, Enterococcaceae, and yeast-like fungi. The minimum bactericidal concentrations (MBCs) ranged from 0.794 µg/ml to 0.198 µg/ml (KC-246) and from 2.093 µg/ml to 0.523 µg/ml (KC-248).
- Open Access
- 8 January 2024
- Published by Springer Nature in Research Square
Molecular Model of Inhibition of the Catalytic Fragment of Domain ExoN of Exoribonuclease of Virus SARS-CoV-2-betacoronavirus B by Drug FS-1 Containing Molecular Iodine and Lithium and Magnesium Halides.
Background: The 2020 pandemic has clearly shown the relevance of creating antiviral drugs. One of the targets of the drug is the active center of the vital enzymes of the virus. Such drugs include the antibacterial. and antiviral drug FS-1. Method: For the study, a coronavirus cell culture line was used. The VERO C1008 cell culture [Vero 76, clone E6, Vero E6] (ATCC® CRL1586™) was adapted for use in the COVID-19 model. Antiviral activity of TI investigates in vitro by therapeutic, prophylactic and virus inhibition scheme. Structures modeling the mechanism anticoronavirus effect of drug FS-1 are calculated using the approach DFT/B3PW91/6-31G**. Total energies of the complexes in aqueous solution calculated using model COSMO. Result: Drug FS-1 substance has virus inhibitory activity at a concentration of 3.36 mg/ml in Vero E6 cell culture against coronavirus infection COVID-19 (strain hCoV19/Kazakhstan/KazNAU-NSCEDI-481/2020) in a dose of 100 TCID50/0.2 ml. For the genome of the virus taken from isolate of SARS-CoV-2/INMI1/human/2020/ITA, the frequency of occurrence of nucleotide triplets has been analyzed. The most common triplet is AAA (281). Using the DFT/B3PW91/6-31G** approach, it is shown the active complexes of drug FS-1: [MgI3LiII2]+ and Li(Cl)I3, can segregate from the dextrin helix and can form a complex with donor-active atoms of the triplet AAA of viral RNA. Complexes of active center of nanocomplex FS-1 with triplet AAA destroy the complex formed by a phosphate group of viral RNA and a catalytic fragment of domain ExoN of exoribonuclease, and form a new nucleoprotein complex where lithium chloride and [MgI3LiII2]+ bind both viral RNA and magnesium ions of the catalytic fragment of domain ExoN of exoribonuclease. The conditions of cleavage of RNA are violated. Conclusion Results of experimental research and the proposed molecular model show that the nanocomplex of drug FS-1 have anticoronavirus effect.
- 8 January 2024
- Published by Springer Nature in Research Square
Open AccessMolecular Model of Inhibition of the Catalytic Fragment of Domain ExoN of Exoribonuclease of Virus SARS-CoV-2-betacoronavirus B by Drug FS-1 Containing Molecular Iodine and Lithium and Magnesium Halides.
Background: The 2020 pandemic has clearly shown the relevance of creating antiviral drugs. One of the targets of the drug is the active center of the vital enzymes of the virus. Such drugs include the antibacterial. and antiviral drug FS-1. Method: For the study, a coronavirus cell culture line was used. The VERO C1008 cell culture [Vero 76, clone E6, Vero E6] (ATCC® CRL1586™) was adapted for use in the COVID-19 model. Antiviral activity of TI investigates in vitro by therapeutic, prophylactic and virus inhibition scheme. Structures modeling the mechanism anticoronavirus effect of drug FS-1 are calculated using the approach DFT/B3PW91/6-31G**. Total energies of the complexes in aqueous solution calculated using model COSMO. Result: Drug FS-1 substance has virus inhibitory activity at a concentration of 3.36 mg/ml in Vero E6 cell culture against coronavirus infection COVID-19 (strain hCoV19/Kazakhstan/KazNAU-NSCEDI-481/2020) in a dose of 100 TCID50/0.2 ml. For the genome of the virus taken from isolate of SARS-CoV-2/INMI1/human/2020/ITA, the frequency of occurrence of nucleotide triplets has been analyzed. The most common triplet is AAA (281). Using the DFT/B3PW91/6-31G** approach, it is shown the active complexes of drug FS-1: [MgI3LiII2]+ and Li(Cl)I3, can segregate from the dextrin helix and can form a complex with donor-active atoms of the triplet AAA of viral RNA. Complexes of active center of nanocomplex FS-1 with triplet AAA destroy the complex formed by a phosphate group of viral RNA and a catalytic fragment of domain ExoN of exoribonuclease, and form a new nucleoprotein complex where lithium chloride and [MgI3LiII2]+ bind both viral RNA and magnesium ions of the catalytic fragment of domain ExoN of exoribonuclease. The conditions of cleavage of RNA are violated. Conclusion Results of experimental research and the proposed molecular model show that the nanocomplex of drug FS-1 have anticoronavirus effect.
- Open Access
- 1 January 2024
- Published by Indian Pharmaceutical Association - IPA
- Vol. 13 (3) , 01-12
Molecular Model of Inhibition of the Catalytic Fragment of Domain ExoN of Exoribonuclease of Virus SARS-CoV-2-Betacoronavirus B by Drug FS-1 Containing Molecular Iodine and Lithium and Magnesium Halides.
Model of inhibition of the catalytic fragment of domain ExoN of exoribonuclease of virus SARS-CoV-2-betacoronavirus B by Drug FS-1 containing molecular iodine and lithium and magnesium halides was proposed by the molecular modeling method. For the genome of the virus taken from isolate of SARS-CoV-2/INMI1/human/2020/ITA, the frequency of occurrence of nucleotide triplets has been analysed. The most common triplet is AAA (281). Using the DFT/B3PW91/6-31G** approach, it is shown the active complexes of drug FS-1: (MgI3LiII2)+ and Li(Cl)I3, can segregate from the dextrin helix and can form a complex with donor-active atoms of the triplet AAA of viral RNA. Complexes of active center of nanocomplex FS-1 with triplet AAA destroy the complex formed by a phosphate group of viral RNA and a catalytic fragment of domain ExoN of exoribonuclease and form a new nucleoprotein complex where lithium chloride and (MgI3LiII2)+ bind both viral RNA and magnesium ions of the catalytic fragment of domain ExoN of exoribonuclease. The conditions of cleavage of RNA are violated. The drug FS-1 substance has virus inhibitory activity at a concentration of 3.36 mg/ml in Vero E6 cell culture against coronavirus infection COVID-19 (strain hCoV19/Kazakhstan/KazNAU-NSCEDI-481/2020) in a dose of 100 TCID50/0.2 ml. Result of experimental research and the proposed molecular model show that the nanocomplex of drug FS-1 have anticoronavirus effect.
- 1 January 2024
- Published by Indian Pharmaceutical Association - IPA
- Vol. 13 (3) , 01-12
Open AccessMolecular Model of Inhibition of the Catalytic Fragment of Domain ExoN of Exoribonuclease of Virus SARS-CoV-2-Betacoronavirus B by Drug FS-1 Containing Molecular Iodine and Lithium and Magnesium Halides.
Model of inhibition of the catalytic fragment of domain ExoN of exoribonuclease of virus SARS-CoV-2-betacoronavirus B by Drug FS-1 containing molecular iodine and lithium and magnesium halides was proposed by the molecular modeling method. For the genome of the virus taken from isolate of SARS-CoV-2/INMI1/human/2020/ITA, the frequency of occurrence of nucleotide triplets has been analysed. The most common triplet is AAA (281). Using the DFT/B3PW91/6-31G** approach, it is shown the active complexes of drug FS-1: (MgI3LiII2)+ and Li(Cl)I3, can segregate from the dextrin helix and can form a complex with donor-active atoms of the triplet AAA of viral RNA. Complexes of active center of nanocomplex FS-1 with triplet AAA destroy the complex formed by a phosphate group of viral RNA and a catalytic fragment of domain ExoN of exoribonuclease and form a new nucleoprotein complex where lithium chloride and (MgI3LiII2)+ bind both viral RNA and magnesium ions of the catalytic fragment of domain ExoN of exoribonuclease. The conditions of cleavage of RNA are violated. The drug FS-1 substance has virus inhibitory activity at a concentration of 3.36 mg/ml in Vero E6 cell culture against coronavirus infection COVID-19 (strain hCoV19/Kazakhstan/KazNAU-NSCEDI-481/2020) in a dose of 100 TCID50/0.2 ml. Result of experimental research and the proposed molecular model show that the nanocomplex of drug FS-1 have anticoronavirus effect.
- Open Access
- 20 February 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (9) , 8617-8624
Molecular Modeling of the Anti-HIV Activity Mechanism of Iodine-Containing Drugs Armenicum and FS-1
Drugs Armenicum and FS-1 are a solution of ionic nanostructured complexes of alpha-dextrin. In the active centers of these drugs, located inside the dextrin helix, molecular iodine has such an electronic form that minimizes toxic effects in the human body, so these drugs can be used for parenteral and oral administration. On the human lymphoblastoid cell line MT-2, the effect of the antiviral action of FS-1 against HIV-1 was established. Literature data on the results of treatment of people with HIV infection with Armenicum are presented. The mechanism of anti-HIV action of drugs Armenicum and FS-1 was proposed by the molecular modeling method. Using the DFT/B3PW91/6-31G** approach, it was shown that LiI(Cl)I2 active center drugs of Armenicum and FS-1 can be segregated from the dextrin helix and can form a complex with the ACT nucleotide triplet, which is part of a specific fragment of viral DNA that binds to the active center of integrase. The formation of this complex is a key moment in the mechanism of anti-HIV drug action. Molecular iodine and lithium halide, which are part of the active complexes, inhibit the active center of the catalytic domain of the integrase. A new nucleoprotein complex is created that destroys the nucleoprotein preintegration complex (PIC) and inhibits the HIV DNA and the active center of the catalytic domain, while a new N-I bond appears in the viral DNA in the cytosine pyrimidine cycle.
- 20 February 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (9) , 8617-8624
Open AccessMolecular Modeling of the Anti-HIV Activity Mechanism of Iodine-Containing Drugs Armenicum and FS-1
Drugs Armenicum and FS-1 are a solution of ionic nanostructured complexes of alpha-dextrin. In the active centers of these drugs, located inside the dextrin helix, molecular iodine has such an electronic form that minimizes toxic effects in the human body, so these drugs can be used for parenteral and oral administration. On the human lymphoblastoid cell line MT-2, the effect of the antiviral action of FS-1 against HIV-1 was established. Literature data on the results of treatment of people with HIV infection with Armenicum are presented. The mechanism of anti-HIV action of drugs Armenicum and FS-1 was proposed by the molecular modeling method. Using the DFT/B3PW91/6-31G** approach, it was shown that LiI(Cl)I2 active center drugs of Armenicum and FS-1 can be segregated from the dextrin helix and can form a complex with the ACT nucleotide triplet, which is part of a specific fragment of viral DNA that binds to the active center of integrase. The formation of this complex is a key moment in the mechanism of anti-HIV drug action. Molecular iodine and lithium halide, which are part of the active complexes, inhibit the active center of the catalytic domain of the integrase. A new nucleoprotein complex is created that destroys the nucleoprotein preintegration complex (PIC) and inhibits the HIV DNA and the active center of the catalytic domain, while a new N-I bond appears in the viral DNA in the cytosine pyrimidine cycle.
- Open Access
- 13 December 2021
- Published by MDPI AG in Quantum Reports
- Vol. 3 (4) , 746-812
Structure of the Active Nanocomplex of Antiviral and Anti-Infectious Iodine-Containing Drug FS-1
Chromatographic analysis shows that the ionic nanostructured complex of the FS-1 drug contains nanocomplexes of α-dextrin with a size of ~40–48 Å. Based on good agreement between the UV spectra of the model structures and the experimental spectrum of the FS-1 drug, the structure of the active FS-1 nanocomplex is proposed. The structure of the active centers of the drug in the dextrin ring was calculated using the quantum-chemical approach DFT/B3PW91. The active centers, i.e., a complex of molecular iodine with lithium halide (I), a binuclear complex of magnesium and lithium containing molecular iodine, triiodide (II), and triiodide (III), are located inside the dextrin helix. The polypeptide outside the dextrin helix forms a hydrogen bond with dextrin in Complex I and coordinates the molecular iodine in Complex II. It is revealed that the active centers of the FS-1drug can be segregated from the dextrin helix and form complexes with DNA nucleotide triplets. The active centers of the FS-1 drug are only segregated on specific sections of DNA. The formation of a complex between the DNA nucleotide and the active center of FS-1 is a key stage in the mechanisms of anti-HIV, anti-coronavirus (Complex I) and antibacterial action (Complex II).
- 13 December 2021
- Published by MDPI AG in Quantum Reports
- Vol. 3 (4) , 746-812
Open AccessStructure of the Active Nanocomplex of Antiviral and Anti-Infectious Iodine-Containing Drug FS-1
Chromatographic analysis shows that the ionic nanostructured complex of the FS-1 drug contains nanocomplexes of α-dextrin with a size of ~40–48 Å. Based on good agreement between the UV spectra of the model structures and the experimental spectrum of the FS-1 drug, the structure of the active FS-1 nanocomplex is proposed. The structure of the active centers of the drug in the dextrin ring was calculated using the quantum-chemical approach DFT/B3PW91. The active centers, i.e., a complex of molecular iodine with lithium halide (I), a binuclear complex of magnesium and lithium containing molecular iodine, triiodide (II), and triiodide (III), are located inside the dextrin helix. The polypeptide outside the dextrin helix forms a hydrogen bond with dextrin in Complex I and coordinates the molecular iodine in Complex II. It is revealed that the active centers of the FS-1drug can be segregated from the dextrin helix and form complexes with DNA nucleotide triplets. The active centers of the FS-1 drug are only segregated on specific sections of DNA. The formation of a complex between the DNA nucleotide and the active center of FS-1 is a key stage in the mechanisms of anti-HIV, anti-coronavirus (Complex I) and antibacterial action (Complex II).
- 17 October 2012
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1033, 321-330
The effect of the amphoteric properties of amino acids in the zwitterionic form on the structure of iodine complex compounds in aqueous solutions
- 17 October 2012
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1033, 321-330
The effect of the amphoteric properties of amino acids in the zwitterionic form on the structure of iodine complex compounds in aqueous solutions
- 18 January 2012
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 59 (1) , 29-34
Effect of organic ligands with conjugated π‐bonds on the structure of iodine–α‐dextrin complexes
Using X-ray data for iodine–α-dextrin complexes and the results of quantum chemical ab initio restricted Hartree–Fock/3-21G** level calculations, a model of drug active complex (AC) Armenicum with anti-HIV action was proposed. It was suggested that the drug AC contains molecular iodine allocated inside of α-dextrin helix and coordinated by lithium halogenides and a protein component of lymphocyte ribosomes. The electronic structure of I2 in this complex differs from its characteristics in complexes with organic ligands or the free I2. In the considered ACs, the molecular iodine displays acceptor (donor) properties toward the α-dextrins (lithium halogenides). A mechanism of Armenicum anti-HIV action is suggested. Under the influence of molecular iodine-containing drug AC, the structure of HIV DNA is modified—it becomes more π-donor-active against proteins and peptide nucleotides of viral DNA form a stable complex with molecular iodine and lithium halogenides.
- 18 January 2012
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 59 (1) , 29-34
Effect of organic ligands with conjugated π‐bonds on the structure of iodine–α‐dextrin complexes
Using X-ray data for iodine–α-dextrin complexes and the results of quantum chemical ab initio restricted Hartree–Fock/3-21G** level calculations, a model of drug active complex (AC) Armenicum with anti-HIV action was proposed. It was suggested that the drug AC contains molecular iodine allocated inside of α-dextrin helix and coordinated by lithium halogenides and a protein component of lymphocyte ribosomes. The electronic structure of I2 in this complex differs from its characteristics in complexes with organic ligands or the free I2. In the considered ACs, the molecular iodine displays acceptor (donor) properties toward the α-dextrins (lithium halogenides). A mechanism of Armenicum anti-HIV action is suggested. Under the influence of molecular iodine-containing drug AC, the structure of HIV DNA is modified—it becomes more π-donor-active against proteins and peptide nucleotides of viral DNA form a stable complex with molecular iodine and lithium halogenides.